Welcome to our dedicated page for Coya Therapeutics news (Ticker: COYA), a resource for investors and traders seeking the latest updates and insights on Coya Therapeutics stock.
Coya Therapeutics, Inc. (NASDAQ: COYA) is a clinical-stage biotechnology company advancing novel therapies that modulate regulatory T cells (Tregs) to treat neurodegenerative, autoimmune, and metabolic disorders. This page serves as the definitive source for official updates and analysis on COYA's progress in developing innovative immunology solutions.
Investors and researchers will find timely updates on clinical trial milestones, regulatory developments, and strategic collaborations. Our curated news collection includes verified information on therapy pipeline advancements, intellectual property updates, and financial disclosures essential for evaluating this innovative biotech company.
Key content focuses on COYA's multi-modality Treg platform developments, partnership announcements with research institutions, and progress toward addressing high-need conditions like ALS and Alzheimer's disease. All materials maintain journalistic rigor while avoiding speculative commentary.
Bookmark this page for structured access to COYA's latest scientific advancements and corporate developments. Check regularly for updates on this pioneering company's efforts to translate Treg research into transformative therapies.
Coya Therapeutics (NASDAQ: COYA) has announced the publication of a significant research study examining the relationship between inflammation, oxidative stress, and Parkinson's Disease (PD) progression. The study, partially funded by Coya and published in Frontiers of Immunology, reveals important findings about immune dysfunction in PD pathogenesis.
The research demonstrates that peripheral blood monocytes from PD patients show distinct inflammatory patterns compared to healthy controls, with key findings including: upregulation of pro-inflammatory cytokines (IL-6 and IL-1b), increased expression of chemokine receptor CCR2, and varying levels of oxidative stress markers throughout disease progression.
The company is developing COYA 302, a dual immunomodulatory treatment designed to enhance regulatory T cell (Treg) function and suppress inflammation produced by activated monocytes and macrophages. This approach aligns with the study's findings regarding the role of peripheral inflammation in PD pathophysiology.
Coya Therapeutics (NASDAQ: COYA), a clinical-stage biotech company focused on developing biologics for regulatory T cell function enhancement, has announced its participation in the upcoming BTIG Virtual Biotechnology Conference scheduled for July 29-30, 2025.
Interested parties can schedule one-on-one meetings with Coya's management team through their BTIG representatives.
Coya Therapeutics (NASDAQ: COYA), a clinical-stage biotech company focused on developing biologics for regulatory T cell function enhancement, announces its participation in the H.C. Wainwright 3rd Annual BioConnect Conference on May 20, 2025. CEO Arun Swaminathan will engage in a fireside chat at 12:30pm ET at the Nasdaq World Headquarters in New York City.
The presentation will be available via webcast, with management offering one-on-one meeting opportunities. The webcast will be accessible through Coya's website and remain available for 90 days after the event.
Coya Therapeutics (NASDAQ: COYA), a clinical-stage biotech company focused on developing biologics for regulatory T cell function enhancement, has announced its participation in two upcoming conferences in May 2025. The company's leadership, including CEO Dr. Arun Swaminathan and CFO David Snyder, will be available for one-on-one meetings with registered investors at:
1. The D. Boral Capital Inaugural Global Conference on May 14, 2025, at The Plaza Hotel in New York
2. The Mizuho Neuro & Opthalmology Summit from May 20-21, 2025, at the Park Lane Hotel in New York
Coya Therapeutics (NASDAQ: COYA) has announced positive interim results from an investigator-initiated open-label study testing low-dose IL-2 and CTLA4-Ig combination treatment in Frontotemporal Dementia (FTD) patients. The study, conducted at Houston Methodist Neurological Institute, showed promising results in the first cohort of 5 patients.
Key findings include:
- Statistically significant increase in Treg numbers and suppressive function
- Minimal to no cognitive decline throughout the study period
- Well-tolerated treatment with no serious adverse events
- All 5 patients completed the 22-week treatment course
This is particularly notable as FTD patients typically experience rapid cognitive decline, with historical data showing an average 3.57-point worsening over 12 months on the CDR-FTLD scale. The treatment's success in maintaining cognitive function suggests potential therapeutic value for FTD, which currently has no approved treatments.
Coya Therapeutics (NASDAQ: COYA) has published research results for COYA 303, a novel biologic combination of low-dose interleukin 2 (LD IL-2) and GLP-1 receptor agonist (GLP-1RA), designed to enhance regulatory T cell (Treg) function in autoimmune and neurodegenerative diseases.
The study, conducted at Houston Methodist Research Institute, demonstrated that COYA 303 achieved a 42% increase in Treg suppressive function, significantly outperforming individual components (LD IL-2 at 15% and GLP-1RA at 20%). The combination therapy also showed enhanced Treg survival through reduced BAX transcript levels and inhibition of Treg apoptosis.
The research suggests COYA 303 could offer a differentiated approach for conditions like Alzheimer's Disease, where GLP-1 RAs have shown promise, by combining anti-inflammatory effects with enhanced Treg survival and function.
Coya Therapeutics (NASDAQ: COYA), a clinical-stage biotechnology company focused on regulatory T cell (Treg) function enhancement, has announced an upcoming presentation at the ADPD 2025 conference in Vienna.
Principal Investigator Dr. Alireza Faridar from Houston Methodist Hospital will present progress updates on a Phase II clinical trial investigating low-dose IL-2 treatment in patients with mild to moderate Alzheimer's disease. The presentation is scheduled for April 5, 2025.
FAQ
What is the current stock price of Coya Therapeutics (COYA)?
What is the market cap of Coya Therapeutics (COYA)?
